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Material and methods. Fourteen obese subjects and 11 age-matched lean subjects, aswell as
12 T2D obese subjects and 7 age-matched lean subjects were recruited. Global DNA
methylation levels were measured in a cell type-specific manner by flow cytometry. We
validated theassayagainstmassspectrometrymeasuresof the total 5-methylcytosinecontent
in cultured cells treated with the hypomethylation agent decitabine (r = 0.97, p < 0.001).
Results. Global DNA methylation in peripheral blood mononuclear cells, monocytes,
lymphocytes or T cells was not altered in obese or T2D subjects. However, analysis of blood
fractions from lean, obese, and T2D subjects showed increased methylation levels in B cells
from obese and T2D subjects and in natural killer cells from T2D patients. In these cell types,
DNA methylation levels were positively correlated with insulin resistance, suggesting an
association between DNAmethylation changes, immune function andmetabolic dysfunction.Keywords:
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the immune system in a cell type-specific manner. These changes could contribute to the
altered immune functions associated with obesity and insulin resistance.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The immune system is composed of a wide variety of cell
types, each possessing a specific gene expression signature
determined by epigenetic processes such as DNAmethylation
and histone modification [1]. Through the control of chroma-
tin structure, epigenetic processes modulate the access of
DNA-binding transcription factors, thereby selecting for
transcriptional activation or repression of, for example,
lineage-specific genes. Studies investigating the DNA methy-
lome of peripheral blood mononuclear cells (PBMCs) have
shown specific methylation patterns at genes important for
immune function and further suggested that alteration in
DNA methylation is likely to be an important mechanism
contributing to the inter-individual variation in immune cells
function [2,3].
Obesity, characterized by an increased adiposity over lean
mass, is associated with epigenetic variability in blood [4–9]. It
is now clear that immune cells participate to the chronic, low-
grade systemic inflammation observed in obesity, with
infiltration of macrophages in adipose tissue promoting
inflammation [10]. Adipose tissue macrophages contribute to
the etiology of insulin resistance through the secretion of pro-
inflammatory cytokines, such as tumor necrosis factor-α or
interleukin-6, known down-regulators of insulin signaling
[11]. The role of immune cells in the development of insulin
resistance is not limited to macrophages. Both B and T
lymphocytes have also been shown to be important contrib-
utors to the inflammatory process and the resulting insulin
resistance in metabolically active tissues, and in particular in
adipose tissue [12,13].
In studies investigating DNA methylation in blood from
subjects with metabolic dysfunction, DNA methylation was
exclusively analyzed in whole PBMC fractions, which are
composed of numerous cell types. However, global DNA
methylation measures made from whole PBMC fractions
could be obscured by potential changes in blood cell types
counts [14]. Given that obesity and type 2 diabetes (T2D)
were found to be associated with a remodeling of blood
celltype counts [15,16] and that leukocyte sub-populations
exhibit a specific global DNA methylation signature [17],
altered DNA methylation in whole PBMC fractions could
simplymirror a change in the frequency of certain leukocytes'
sub-populations.
In the present study, we aimed to use a cell-specific assay
to determine the global DNA methylation profile of the
different PBMCs' sub-types in obese and T2D individuals.
Using a monoclonal antibody to 5-methylcytosine (5meC) and
flow cytometry, we provide the first measurement of relative
global DNA methylation levels in individual cell types within
PBMCs of lean, obese and T2D subjects.2. Material and methods
2.1. Study population
This project was approved by the Ethics Committee from the
Capital Region of Denmark (reference number H-1-2011-077).
Forty-four male subjects, aged 18–60 were recruited by local
advertisement on university campuses or local hospitals and
informed consent was obtained from the participants.
Participants were free of recent illness, and infectious or
inflammatory diseases, other than metabolic disorders, that
might affect their immune system. Bodymass index (BMI) and
diagnosis of T2D were used to generate 4 groups: 14 obese
males (OBESE, age = 35.1 ± 6.7 yr, BMI = 36.3 ± 6.3 kg/m2,
non-diabetic/healthy) and 11 age-matched lean males (LEAN,
age = 34.8 ± 3.0 yr, BMI = 23.0 ± 1.4 kg/m2, non-diabetic/
healthy) as well as 12 patients with type 2 diabetes (T2D,
age = 44.1 ± 6.5 yr, BMI = 34.9 ± 4.8 kg/m2) or 7 age-matched
lean subjects (LEAN, age = 44.1 ± 6.0 yr, BMI = 23.7 ± 2.2 kg/m2,
non-diabetic/healthy) were recruited for this study.
2.2. Sample collection
Blood samples were obtained by venipuncture from an
antecubital vein and collected on ethylenediaminetetraacetic
acid-treated tubes (BD vacutainer, USA) or acid-citrate-dextrose
treated tubes (ACD, BD vacutainer, USA) followed by
PBMCs isolation by Ficoll gradient centrifugation as previously
described [18].
2.3. Full blood cell count and insulin resistance index
In small subgroups, differential cell count was performed
using a Sysmex XE-2100 automated hematology analyzer
(Sysmex, USA) for the determination of the frequency of
neutrophils, monocytes, lymphocytes and T helper (CD3/CD4
double positive), T cytotoxic cells (CD3/CD8 double positive), B
cells (CD45/CD19/CD20 triple positive) and NK cells (CD3
negative, CD45/16/56 triple positive). Fasting glucose and
insulin levels were measured using automated analyzers
(Beckman LX analyzer, Beckman Coulter, USA and Immulite
2000, Diagnostic Products Corporation, USA respectively) and
the level of insulin resistance was calculated using the
Homeostasis Model Assessment (HOMA-IR) [19].
2.4. Cell culture
The colorectal cancer cell line RKO (ATCC, USA) was main-
tained in Dulbecco's modified Eagle's medium (DMEM, Gibco,
Life Technologies, USA) supplemented with 25 mM glucose,
10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin, 100 ug/
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ogies, USA) and grown at 37 °C in 5% CO2. Cells were treated
every 24 h for a period of 72 h by replacing media supple-
mented with 2.5 uM decitabine (5-aza-2′deoxycytidine,
Sigma-Aldrich, Australia) freshly prepared in 50% filter
sterilized acetic acid (Sigma-Aldrich, Australia). Cells were
harvested at daily time points before and during treatment
and at 3 days following drug withdrawal.
The human T lymphocyte cell line Jurkat (ATCC, USA) was
maintained in RPMI 1640 (Gibco, Life Technologies, USA)
supplemented with penicillin (100 U/mL), streptomycin
(100 ug/mL), L-glutamine (1 mmol/mL) and 10% FBS. The
culture medium was refreshed every third day and the cell
density was maintained below 1 million cells/mL. Twenty-
four hours after the last passage, cells were treated with
2.5 uM decitabine as described above and harvested at
different time points up to 52 h.
2.5. Global methylation quantification by flow cytometry
Global methylation in PBMCs, RKO and Jurkat cells was
quantified as previously described with slight modifications
[20]. Cryopreserved PBMCs were quickly thawed at 37 °C,
transferred into culture medium and washed twice in RPMI
10% FBS. For RKO cells, cells were detached from the culture
vessel by incubating with trypsin (0.25%, Gibco, Life Technol-
ogies, USA) at 37 °C for 5 min. Cells were thenwashed twice in
Dulbecco's phosphate-buffered saline (D-PBS, Sigma-Aldrich,
Australia) with 1% BSA. For Jurkat cells, cells were transferred
to a new sterile tube and washed twice in D-PBS with 1% BSA.
Cell viability was assessed by visual inspection using
trypan blue staining (Sigma-Aldrich, Australia) and density
was normalized to a maximum of 5 million cells per mL. After
30 min at 37 °C, 5% CO2, cells were fixed in 2% paraformalde-
hyde (PFA, Sigma-Aldrich, Australia) in D-PBS for 10 min at
37 °C. After two washes using D-PBS with 1% bovine serum
albumin (BSA, Sigma-Aldrich, Australia) and 0.1% Tween 20
(Sigma-Aldrich, Australia), cells were permeabilized in 100%
methanol (Sigma-Aldrich, Australia) at −20 °C for 30 min.
After three additional washes, cells were incubated at 37 °C in
2 N HCl for 30 min and then transferred into 0.1 M of borate
buffer for 5 min. After three additional washes the PBMCs
were stained with a combination of anti CD3-phycoerythrin
conjugated, CD8- and CD14-peridinin chlorophyll conjugated,
CD4- and CD19-allophycocyanin conjugated (all from BD,
USA). Stained PBMCs, RKO and Jurkat cells were further
stained with unconjugated anti-5-methylcytosine (5meC,
AbD serotec, Bio-Rad, USA) or its corresponding isotype
control (Mouse IgG1, BD, USA). Both unconjugated antibodies
were labeled using a labeling kit according to the manufac-
turer's instructions (Zenon Alexa Fluor 488 Mouse IgG1
labeling kit, Molecular Probes, Life Technologies, Australia).
Cells were incubated with the different antibodies or their
corresponding isotype controls for 20 min at room temper-
ature in the dark. After two more washes, they were
resuspended in 400 uL of 1% PFA in D-PBS and acquired
immediately on a flow cytometer (FACS Calibur, BD, USA).
All data were analyzed using FlowJo version 10 (Tree Star,
USA) and Cytobank (Cytobank Inc., USA). Lymphocytes and
monocytes were gated based on their size and granularity.Monocytes were further gated based on CD14 positivity.
Lymphocytes CD3+CD4+ were considered as T helper cells,
CD3+CD8+ as T cytotoxic cells, CD3−CD19+ as B cells and CD3−
CD8+ as natural killer (NK) cells. For RKO or Jurkat cells, the
population was gated based on size and granularity. In each
population the median fluorescence intensity (MFI) was
measured and normalized by theMFI from the isotype control.
2.6. Global methylation quantification by LC-MS/MS
Global methylation in RKO cells was quantified as previously
described using liquid chromatography tandem mass spec-
trometry (LC-MS/MS) [21]. The absolute quantity of 5-methyl-
2′-deoxycytidine (5mdC; global methylation) was determined
as a percentage of 2′-deoxycytidine plus 5mdC in genomic
DNA extracted from RKO cells by phenol-chloroform extrac-
tion using LC-MS/MS as previously published [22]. This
involved the in-house biosynthesis of [15N3]-dC and [15N3]-
5mdC internal standards and a one-step digestion of 1 ug
genomic DNA spiked with [U-15N]-internal standards into
deoxyribonucleosides. Analyses were performed using an
Ultra High Performance Liquid Chromatography Accela
Pump (Thermo Finnigan, USA) and HTC PAL (CTC Analytics,
USA) autosampler coupled directly to a TSQ Quantum Access
triple quadrupole mass spectrometer (Thermo Finnigan, USA)
in the positive ion mode via an electrospray interface. Data
were processed using the Quanbrowser function of the
Xcalibur Software package v2.0.7 (Thermo Finnigan, USA).
2.7. Bisulfite sequencing of DNA from isolated B-cells
PBMCs were resuspended in PBS 1% BSA and stained with
anti-CD19 APC (BD Biosciences, Europe). Stained cells were
washed twice in PBS 1% BSA and resuspended in 400 uL of PBS
1% BSA prior to sorting on a FACS-Aria (BD Biosciences,
Europe). Genomic DNA was purified from B-cells using
DNeasy Blood & Tissue Kit (Qiagen, Denmark). Bisulfite
conversion was performed using the EZ DNA methylation-
lightning kit (Zymoresearch, Germany) according to the
manufacturer's protocol. Regions corresponding to TFAM
(Transcription factor A, mitochondria), GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase), UBASH3a (ubiquitin-
associated and SH3 domain-containing protein A) and TRIM3
(tripartite motif-containing 3) were amplified using the respec-
tive primers: Forward GGGGATAGAGGTGGTTTAATAG and
Reverse AAACACTATAAAAAATCTACTAACATC, Forward
GGGAGAAAGTAGGGTTGGTTATTAG and Reverse
TCCCTAACCTCCCGAATTTCTCTC, Forward ATAGATAAGGA-
GATTGGGATTTAGG and Reverse CAATTTTCAAAATTCTATT-
TACAAAATACT, Forward GTTTTGGGTATTGTTTTTTTGT and
Reverse ATCTCAAAAATTAAAATAAAACTCC. Purified PCR
products were prepared for sequencing using the TruSeq DNA
preparation protocol adapted to low input concentrations
(Illumina, USA). Samples were sequenced using a MiSeq
sequencer (Illumina, USA). Fastq files were analyzed by FastQC
version 0.9, and adapters/primers identified were removed
by Trimmomatic 0.30. Read ends were clipped to remove
nucleotides with a score below 3, and an average score above
15 across 4 bases. The QCed reads were mapped by Bismark
version 10.0 using bowtie2 version 2.2.2, allowing 1mismatch in
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very sensitive mode using -D 50 and -R 10. Bismark was also
used to process the resulting alignment files, generating a
report onallmethylatedcytosines in the4 sequences (using –CX
and –cytosine_report). Subsequent analyses were done in R
version 3.1.0. For every sample, positions covered by less
than 1000 reads were excluded. For plotting, the mean and the
95% confidence interval were calculated using the adjusted
bootstrap percentile method. Plots were generated using the
ggplot2 package.Fig. 1 – Validation of the 5-methylcytosine quantification
assay using flow cytometry. A— Representative
quantification of 5-methylcytosine levels measured by flow
cytometry in RKO cells treated with decitabine for 72 h and
then left for 3 days after drug withdrawal. B— Correlation
between % of 5-methylcytosine quantified by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
and 5-methylcytosine median fluorescence intensity (MFI)
measured by flow cytometry. C— 5-Methylcytosine MFI
levels measured in Jurkat cells after exposure to decitabine.2.8. Statistical analysis
Results are reported as mean ± standard deviation. All
statistical analyses were performed on the SPSS Statistics
Package Version 21 (IBM, USA) and statistical significance was
set at p < 0.05. The normality of the distribution was tested
using the Skewness and the Kurtosis tests. When the
assumption of normality was violated, log transformation
was performed to achieve normal distribution. The difference
between groups (Lean vs Obese and Lean vs T2D) for
anthropometric and hematological values or global methyla-
tion levels was tested using a Student t test. Correlation levels
were assessed using the Pearson's correlation coefficient.
Bisulfite sequencing results were analyzed for every cytosine
position,wheredifferences between leanandobeseorT2Dwere
tested using the non-parametric Kolmogorov–Smirnov test.3. Results
To determine the global DNAmethylation profile of individual
cell types within PBMCs, we used a method previously
developed in cell lines [20]. We tested this method, that relies
on the assessment of DNA methylation using a monoclonal
antibody to 5meC detected by flow cytometry, against high-
resolution mass spectrometry, which represents, to our
knowledge, the assay having the highest sensitivity and
precision for the quantification of 5meC [23]. DNA methyla-
tion analysis was performed on untreated RKO cells as well as
cells exposed to the DNA hypomethylating agent decitabine
for 24, 48, 72 h and 3 days after drug withdrawal. Pearson's
correlation analysis of the total cytosine methylation levels
measured using both techniques revealed a tight association
(r = 0.97, p = 0.001, Fig. 1A and B). This was confirmed in Jurkat
cells where decitabine effect was successfully detected by flow
cytometry (Fig. 1C), further validating the use of flow
cytometry to monitor global DNA methylation.
We next used this assay to determine global DNA
methylation levels in PBMCs from obese and T2D individuals.
Importantly, because blood global DNA methylation has beenTable 1 – Blood cell counts.
Lean
(n = 4)
Obese
(n = 12)
T2D
(n = 6)
Neutrophils
(% total leukocytes)
51.8 ± 4.5 52.7 ± 8.2 58.7 ± 10.6
Monocytes
(% total leukocytes)
8.9 ± 2.1 7.7 ± 1.7 6.6 ± 1.3
Lymphocytes
(% total leukocytes)
35.5 ± 4.7 35.6 ± 6.5 31.2 ± 10.5
T helper cells
(% total leucocytes)
16.6 ± 3.6 16.2 ± 3.8 15.8 ± 8.4
T cytotoxic cells
(% total leukocytes)
6.4 ± 1.8 10.1 ± 4.1 8.1 ± 3.0
B cells (% total leukocytes) 4.6 ± 1.4 5.4 ± 2.1 4.0 ± 2.9
NK cells (% total leukocytes) 5.9 ± 2.5 4.7 ± 2.8 3.8 ± 1.7
T2D: type 2 diabetes group, NK: natural killer. No significant
differencewas observed between the different groups for any of the
sub-populations reported here.
Fig. 2 – Analysis of 5-methylcytosine levels in peripheral blood mononuclear cells (PBMCs), lymphocytes and monocytes
between lean and obese or type 2 diabetic subjects. A — Representative quantification of 5-methylcytosine levels in PBMCs,
lymphocytes and monocytes (obese group in dark line and lean group in filled gray). B— Comparison of 5-methylcytosine
median fluorescence intensity (MFI) between the lean group (gray) and the obese group (black). C— Representative
quantification of 5-methylcytosine levels in PBMCs, lymphocytes and monocytes (lean group in filled gray and type 2 diabetic
group (T2D) in dark line). D— Comparison of 5-methylcytosine MFI between the lean group (gray) and T2D group (black).
1192 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 3 ( 2 0 1 4 ) 1 1 8 8 – 1 1 9 7
Fig. 3 – Comparison of global methylation in lymphocyte sub-populations between lean and obese or type 2 diabetic patients.
A— Representative 5-methylcytosine levels in T helper, T cytotoxic, B and Natural Killer (NK) cells (lean group in filled gray and
obese group in dark line). B— Comparison of 5-methylcytosine median fluorescence intensity (MFI) between the lean group
(gray) and the obese group (black), *Significantly different from the obese group (p < 0.05). C— Representative 5-methylcytosine
levels inThelper, T cytotoxic, B andNKcells (leangroup in filled grayandT2D indark line). D—Comparisonof 5-methylcytosine
MFI between the lean group (gray) and the T2D group (black), *significantly different from the T2D group (p < 0.05).
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participants to two separate control cohorts of lean and
normal glucose tolerant subjects. In addition, it has previously
been hypothesized that a variation in blood cell counts could
potentially mask an alteration in global methylation in a cell-
type-specific fashion [14].We thus investigated leukocyte sub-
types frequency. However, in our population, blood cell counts
showed similar profile across groups (Table 1, p > 0.05).
We then compared the obese and T2D subjects to their
respective control groups and found no difference in global
DNA methylation levels in the PBMCs fraction (comprising
both lymphocytes and monocytes) or in the lymphocyte or
monocyte populations assessed separately (Fig. 2A and B forFig. 4 – Association between global DNAmethylation in B and NK
5-methylcytosine levels (median fluorescence intensity or MFI) in
C-.Correlationbetween5-methylcytosine levels (MFI) innatural killlean vs obese, n = 11 and n = 14 respectively, Fig. 2C and D for
lean vs T2D, n = 7 and n = 12 respectively, p > 0.05).
We further analyzed global DNA methylation in individual
cell sub-types (T helper, T cytotoxic, B and NK cells). We found
that B cells from obese subjects showed a marked increase in
methylation levels compared to their lean controls (Fig. 3A andB,
n = 14 for obese andn = 11 for lean, p = 0.012), but not Thelper, T
cytotoxic or NK cells (Fig. 3A and B, p > 0.05). In T2D patients we
detected increased methylation levels in B and NK cells (Fig. 3C
and D, n = 12 for T2D and n = 7 for lean, p = 0.022 and p = 0.004
for B cells and NK cells, respectively) but no significant
methylation difference in T helper and T cytotoxic cells (Fig. 3C
andD,p > 0.05).Moreover,we foundthatglobalDNAmethylationlymphocytes and metabolic indices. Correlation between
B lymphocytes and glucose A-, insulin B- and HOMA-IR
er (NK) lymphocytesandglucoseD-, insulinE-andHOMA-IRF-.
Fig. 5 –Analysis of gene specific DNAmethylation in B-cells of lean, obese and type 2 diabetic subjects. Percentmethylation of cytosineswithin the GAPDH, TFAM, UBASH3A and
TRIM3 genes in B-cells from the Lean (Red), Obese (Green) or T2D (Blue) subjects, relative to transcription start site (TSS). Data are shown as mean with 95% confidence interval.
Filled symbols — CpG, Empty symbol— non-CpG, Squares — significantly different from lean group (p < 0,05).
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0.008, n = 16) and insulin resistance (Fig. 4C, HOMA-IR, r = 0.63,
p = 0.009, n = 16) but not with fasting glucose (Fig. 4A), further
favoring a link between B cells and the development of insulin
resistance [12]. A similar trend was also observed in NK cells,
but only reaching near significance for insulin resistance
(Fig. 4F, r = 0.49, p = 0.057, n = 16), whereas no association
was observed with fasting glucose or insulin (Fig. 4D and E).
To determine if global changes of DNA methylation affect
every single cytosine in the genome or are gene-specific, we
analyzed the methylation of a house-keeping gene and genes
shown in other studies to be differentially methylated in
PBMCs from obese (TRIM3, UBASH3A [8]) or insulin resistant
subjects (TFAM). In the regions tested, only few cytosines
residues were found differentially methylated, notably cyto-
sine −235 relative to the transcription start site of the
UBASH3A gene, which was hypermethylated in T2D (Fig. 5).
These data suggest that the global alteration in the DNA
methylome of B lymphocytes is gene-specific.4. Discussion
Numerous studies have reported that global and gene-specific
DNA methylation profiles are altered in blood from obese
individuals, without focusing on specific blood cell sub-
populations [3,6–9,14]. Here, we have used a flow cytometry-
based assay to further determine, in a cell type-specific
manner, the global DNAmethylation profile of blood obtained
from obese and T2D subjects. We provide evidence that
obesity and T2D are associated with a dramatic remodeling of
the epigenome of specific immune cell types.
Previously, Zhao et al. reported that global DNA methyla-
tion in peripheral blood leukocytes, as assessed by bisulfite
pyrosequencing on Alu elements, was associated with insulin
resistance [9]. In our study we did not find any difference in
global DNA methylation for PBMCs, lymphocytes or mono-
cytes between lean, obese or type 2 diabetic individuals. In
view of our results, we can only speculate that the nature of
our assay (interrogating all cytosines versus cytosines within
Alu repeats), participants characteristics, a remodeling of the
blood cell count or the contribution of granulocytes toward the
global DNAmethylation levels (sincewe only included PBMCs)
could be accountable for the difference between our results
and those of Zhao et al. [9]. Given that each blood cell type
exhibits a specific global DNA methylation signature [17], a
variation in blood cell-types frequency could potentially mask
an alteration in global methylation in a cell type-specific
fashion as previously hypothesized [14]. In our population, we
did not observe any difference in blood cell counts across
groups ruling out a potential masking effect of altered blood
cell counts on the global DNA methylation of the whole
PBMC population.
Our gene specific analysis of DNA methylation in B
lymphocytes revealed that global hypermethylation is not
caused by hypermethylation at every single cytosine residue
but instead, are gene- and cytosine-specific. We have previ-
ously reported a similar profile in skeletal muscle after a
single bout of exercise, where global methylation was altered
but not all genes were affected [25]. Similarly, cancer cellsexhibit a global hypomethylation signature, with gene-
specific methylation patterns. In our cohort, we could only
partially replicate previous findings showing thatmethylation
of the TRIM3 and UBASH3A promoters is altered in subjects
with T2D [8]. In our study, methylation of the TRIM3 promoter
was not altered and UBASH3A was moderately affected on
cytosine −235 relative to the transcription start site in T2D.
Given that our analysis was conducted in pure B cell fractions,
the discrepancy could be due to monocytes and other
lymphocytes subpopulations accounting for the changes
detected in whole PBMCs fractions [8].
In the present study, we found that both obese and type 2
diabetic individuals were characterized by increased global
DNA methylation in B cells. Previously, B cells have been
shown to play a central role in the development of insulin
resistance [12], through the production of IgG antibodies and
the activation of T cells and macrophages [13]. It is well
documented that several functions of B cells are epigenetically
regulated and that epigenetic dysregulation in immune cells
has been associated to altered immune function in disease
[26]. Similarly, we found that NK cells, though only in type 2
diabetes, showed increased global methylation. NK cells'
functions can also be epigenetically regulated [27] and NK
cells have been associated with diet-induced obesity and
inflammation further leading to insulin resistance [28,29]. Our
results showing that global DNAmethylation is increased in B
and NK cells suggest that epigenetic changes are involved in
the altered immune function described in obesity and T2D.
This is further supported by the positive correlation we
observed between the level of insulin resistance and global
DNAmethylation in B cells and to a certain extent in NK cells.
Collectively, our results show that insulin resistance is
associated with dramatic epigenetic changes in specific
lymphocyte sub-populations, potentially contributing to the
altered immune function reported in metabolic disorders.
Interestingly, the differences in global DNA methylation were
not found at the whole PBMCs level but in specific cell types.
This stresses the relevance of using cell type-specific assays
when investigating epigenetic signatures in clinical tissue
samples characterized by a high heterogeneity in cell types
frequency and phenotype, such as blood.Authors' contribution
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